Vogel Lotte K, Saebø Mona, Skjelbred Camilla F, Abell Kathrine, Pedersen Esben D K, Vogel Ulla, Kure Elin H
Department of Medical Biochemistry and Genetics, University of Copenhagen, Blegdamsvej 3, Denmark.
BMC Cancer. 2006 Jul 4;6:176. doi: 10.1186/1471-2407-6-176.
It has recently been shown that overexpression of the serine protease, matriptase, in transgenic mice causes a dramatically increased frequency of carcinoma formation. Overexpression of HAI-1 and matriptase together changed the frequency of carcinoma formation to normal. This suggests that the ratio of matriptase to HAI-1 influences the malignant progression. The aim of this study has been to determine the ratio of matriptase to HAI-1 mRNA expression in affected and normal tissue from individuals with colorectal cancer adenomas and carcinomas as well as in healthy individuals, in order to determine at which stages a dysregulated ratio of matriptase/HAI-1 mRNA is present during carcinogenesis.
Using quantitative RT-PCR, we have determined the mRNA levels for matriptase and HAI-1 in colorectal cancer tissue (n = 9), severe dysplasia (n = 15), mild/moderate dysplasia (n = 21) and in normal tissue from the same individuals. In addition, corresponding tissue was examined from healthy volunteers (n = 10). Matriptase and HAI-1 mRNA levels were normalized to beta-actin.
Matriptase mRNA level was lower in carcinomas compared to normal tissue from healthy individuals (p < 0.01). In accordance with this, the matriptase mRNA level was also lower in adenomas/carcinomas combined as compared to their adjacent normal tissue (p < 0.01). HAI-1 mRNA levels in both normal and affected tissue from individuals with severe dysplasia or carcinomas and in affected tissue with mild/moderate dysplasia were all significantly lower than mRNA levels observed in corresponding tissue from healthy control individuals. HAI-1 mRNA was lower in carcinomas as compared to normal tissue from healthy individuals (p < 0.001). HAI-1 mRNA levels were significantly lower in tissue displaying mild/moderate (p < 0.001) and severe (p < 0.01) dysplasia compared to normal tissue from the same patients. Both adenomas and carcinomas displayed a significantly different matriptase/HAI-1 mRNA ratio than corresponding normal tissue from healthy control individuals (p < 0.05). In addition statistically significant difference (p < 0.001) could be observed between mild/moderate and severe adenomas and their adjacent normal tissue.
Our results show that dysregulation of the matriptase/HAI-1 mRNA ratio occurs early during carcinogenesis. Future studies are required to clarify whether the dysregulated matriptase/HAI-1 ratio was causing the malignant progression or is a consequence of the same.
最近研究表明,在转基因小鼠中丝氨酸蛋白酶matriptase的过表达导致癌形成频率显著增加。HAI-1和matriptase共同过表达可使癌形成频率恢复正常。这表明matriptase与HAI-1的比例影响恶性进展。本研究的目的是确定患有结肠直肠癌腺瘤和癌的个体以及健康个体的病变组织和正常组织中matriptase与HAI-1 mRNA表达的比例,以确定在癌变过程的哪个阶段存在matriptase/HAI-1 mRNA比例失调。
使用定量逆转录聚合酶链反应(RT-PCR),我们测定了结肠直肠癌组织(n = 9)、重度发育异常(n = 15)、轻度/中度发育异常(n = 21)以及同一患者正常组织中matriptase和HAI-1的mRNA水平。此外,还检测了健康志愿者(n = 10)的相应组织。matriptase和HAI-1的mRNA水平以β-肌动蛋白为标准进行归一化。
与健康个体的正常组织相比,癌组织中matriptase mRNA水平较低(p < 0.01)。与此一致,腺瘤/癌合并组织中的matriptase mRNA水平也低于其相邻正常组织(p < 0.01)。重度发育异常或癌患者的正常组织和病变组织以及轻度/中度发育异常病变组织中的HAI-1 mRNA水平均显著低于健康对照个体相应组织中的mRNA水平。与健康个体的正常组织相比,癌组织中的HAI-1 mRNA水平较低(p < 0.001)。与同一患者的正常组织相比显示轻度/中度(p < 缉001)和重度(p < 0.01)发育异常的组织中HAI-1 mRNA水平显著较低。腺瘤和癌组织中的matriptase/HAI-1 mRNA比例与健康对照个体的相应正常组织相比均有显著差异(p < 0.05)。此外,在轻度/中度和重度腺瘤与其相邻正常组织之间可观察到统计学上的显著差异(p < 0.001)。
我们的结果表明,matriptase/HAI-1 mRNA比例失调在癌变早期就已发生。未来需要进一步研究以阐明matriptase/HAI-1比例失调是导致恶性进展的原因还是其结果。